Related Experiment Video
Updated: Aug 22, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Oncolytic Zika Virus: New Option for Glioblastoma Treatment
Chao Zhou1,2, Qi Chen1, Yun Chen2
1State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Abstract:
Glioblastoma (GBM) is one of the most aggressive brain tumors and has a high recurrence rate, and effective treatment is urgently needed. GBM stem cells (GSCs) contribute to GBM recurrence as well as therapeutic resistance to radiation and chemotherapy. Several oncolytic viruses (OVs) have been developed and validated in clinical trials with favorable safety profiles and efficacy against GBM. Recently, Zika virus (ZIKV), a mosquito-borne flavivirus, was shown to preferentially target and kill GSCs and showed promising therapeutic effects in treating GBM in preclinical models. In this review, we summarize the known OVs for the treatment of GBM and highlight the major advantages and existing challenges for the clinical development of oncolytic ZIKV.
Insights
Glioblastoma stem cells drive tumor recurrence and treatment resistance. Oncolytic Zika virus shows promise in targeting these cells for effective glioblastoma treatment.
Area of Science:
- Neuro-oncology
- Virology
- Cancer Therapy
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with high recurrence rates, necessitating novel therapeutic strategies.
- Glioblastoma stem cells (GSCs) are implicated in tumor recurrence and resistance to conventional treatments like radiation and chemotherapy.
- Oncolytic viruses (OVs) represent a promising therapeutic avenue for GBM, with several candidates demonstrating safety and efficacy in clinical trials.
Approach:
- This review examines the potential of oncolytic viruses, specifically Zika virus (ZIKV), as a targeted therapy for glioblastoma.
- The review highlights ZIKV's preferential targeting and killing of GSCs, a key factor in GBM's aggressive nature.
- Preclinical models have shown promising therapeutic effects of ZIKV in treating GBM.
Key Points:
- Oncolytic Zika virus (ZIKV) demonstrates selective tropism for Glioblastoma stem cells (GSCs).
- ZIKV exhibits potent oncolytic activity against GSCs, addressing a critical challenge in GBM therapy.
- Preclinical studies indicate ZIKV's therapeutic potential in Glioblastoma models.
Conclusions:
- Oncolytic viruses, particularly ZIKV, offer a novel approach to combatting Glioblastoma.
- Targeting GSCs with ZIKV presents a promising strategy to overcome therapeutic resistance and recurrence in GBM.
- Further clinical development of oncolytic ZIKV for GBM requires addressing existing challenges while leveraging its advantages.
